Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate

  title={Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate},
  author={Kieran Rea and Michelle Roche and David P. Finn},
  journal={British Journal of Pharmacology},
Recent physiological, pharmacological and anatomical studies provide evidence that one of the main roles of the endocannabinoid system in the brain is the regulation of γ‐aminobutyric acid (GABA) and glutamate release. This article aims to review this evidence in the context of its implications for pain. We first provide a brief overview of supraspinal regulation of nociception, followed by a review of the evidence that the brain's endocannabinoid system modulates nociception. We look in detail… 

Participation of the endogenous opioid and cannabinoid systems in neuropathic pain

The results show that DOR and CB2 may be pharmacological targets for the development of new drugs with analgesic activity, but devoid of the psychotropic side effects of traditional opioids and cannabinoid agonists.

Cannabinoids and Pain: Sites and Mechanisms of Action.

β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

This review of the literature suggests that the development of opioid and cannabinoid agonists that bias MOR and CB1R toward G protein signaling cascades and away from β-arrestin interactions may provide a novel mechanism by which to produce analgesia with less severe adverse effects.

Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test

It is shown that GABA in the NC is involved in pain modulation and suggests the existence of a GABAA-mediated inhibitory system in theNC on pain control, and it seems that the antinociceptive effect of WIN 55,212-2 in the formalin test is mediated partly by the activity of local GabAA receptors inThe NC.

The role of the endocannabinoid system in pain.

The general features of the EC system are described as related to pain and nociception and the wealth of preclinical and clinical data involving targeting theEC system is discussed, with focus on modulation of 2-AG signalling via specific enzyme inhibitors and the role of spinal CB2 in chronic pain states.

The role of N-acetylaspartylglutamate (NAAG) in the amygdala

Test the hypothesis that NAAG influences pain processing in this region of the pain perception pathway, which sends elevated levels of glutamate-mediated excitatory transmission to the amygdala during inflammatory pain states through the spinoparabrachial amygdaloid pain pathway.



Endocannabinoid mechanisms of pain modulation

This review will provide a comprehensive evaluation of the roles of the endocannabinoids 2-arachidonoyl-glycerol and anandamide in stress-induced analgesia and provide a functional framework with which to understand the roles in nociceptive processing at the supraspinal level.

Role of endogenous cannabinoids in synaptic signaling.

The synthetic pathways of endocannabinoids are discussed, along with the putative mechanisms of their release, uptake, and degradation, and the fine-grain anatomical distribution of the neuronal cannabinoid receptor CB1 is described in most brain areas, emphasizing its general presynaptic localization and role in controlling neurotransmitter release.

Pain modulation by release of the endogenous cannabinoid anandamide.

Findings indicate that the endogenous cannabinoid anandamide plays an important role in a cannabinergic pain-suppression system existing within the dorsal and lateral PAG, and may have relevance for the treatment of pain, particularly in instances where opiates are ineffective.

Mechanisms of Cannabinoid Inhibition of GABAASynaptic Transmission in the Hippocampus

Recordings of whole-cell voltage-clamp recordings suggest that presynaptic CB1 receptors reduce GABAA- but not GABAB-mediated synaptic inhibition of CA1 pyramidal neurons by inhibiting VDCCs located on inhibitory nerve terminals.

An analgesia circuit activated by cannabinoids

It is shown that a brainstem circuit that contributes to the pain-suppressing effects of morphine is also required for the analgesic effects of cannabinoids, and that cannabinoids are indeed centrally acting analgesics with a new mechanism of action.

Cannabinoid Receptor Type 1 Located on Presynaptic Terminals of Principal Neurons in the Forebrain Controls Glutamatergic Synaptic Transmission

Exitatory synaptic transmission in forebrain areas is directly modulated by CB1 expressed on presynaptic axon terminals originating from glutamatergic neurons, providing direct evidence that activation of CB1 on terminals of principal neurons controls excited synaptic responses in the forebrain.

Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse.

The results indicate that the mechanisms underlying cannabinoid action in the LA partly resemble those observed in the nucleus accumbens and differ from those described for the hippocampus, and modulate both excitatory and inhibitory synaptic transmission via CB1.

Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats

An endocannabinoid mechanism for stress-induced analgesia

The results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia, and identify monoacylglycerol lipase as a previously unrecognized therapeutic target.